Meropenem + Sulbactam
MEROKWIK-S (Meropenem + Sulbactam) is a combination therapy used to treat a wide range of bacterial infections, especially those caused by multi-drug resistant organisms. Meropenem is a broad-spectrum carbapenem antibiotic and Sulbactam is a beta-lactamase inhibitor. Meropenem is effective against gram-positive and gram-negative bacteria, including aerobic, anaerobic, and ESBL-producing pathogens. Sulbactam protects Meropenem from degradation by bacterial beta-lactamases, enhancing its antimicrobial effectiveness, particularly against resistant strains like Acinetobacter baumannii and Pseudomonas aeruginosa.
Meropenem + Sulbactam provides a synergistic effect, improving treatment outcomes for patients with difficult-to-treat infections.
COMPOSITION:
Meropenem 1g + Sulbactam 500mg
MODE OF ACTION:
Meropenem is a broad-spectrum carbapenem antibiotic that works by binding to penicillin-binding proteins (PBPs) in bacterial cells. These PBPs are essential for the proper formation and maintenance of the bacterial cell wall. By inhibiting the cross-linking of peptidoglycan strands, Meropenem weakens the cell wall, leading to bacterial lysis and death. This bactericidal action makes Meropenem highly effective in treating a variety of infections caused by both gram-positive and gram-negative bacteria, including those resistant to other antibiotics.
Sulbactam is a beta-lactamase inhibitor that enhances Meropenem’s activity by protecting it from degradation by bacterial enzymes known as beta-lactamases. These enzymes, produced by some bacteria, break down beta-lactam antibiotics, rendering them ineffective. Sulbactam binds to these enzymes and prevents them from inactivating Meropenem. It is particularly effective against plasmid-mediated metallo-beta-lactamases (MBLs), which are responsible for antibiotic resistance in bacteria like Acinetobacter baumannii.
When combined, Meropenem and Sulbactam work synergistically. Meropenem disrupts the bacterial cell wall, while Sulbactam ensures that Meropenem remains effective by preventing beta-lactamase-mediated degradation. This combination is particularly useful for treating infections caused by multi-drug-resistant organisms.
INDICATIONS
- Complicated Intra-Abdominal infections (cIAIs)
- Sepsis
- Hospital-acquired infections (HAP)
- Bacterial Meningitis
- Skin and soft tissue infections (SSTI)
Dosage
- Adults: 500 mg to 2 g every 8 hours, based on severity.
- Pediatrics: 10-40 mg/kg every 8 hours, depending on severity.
Disclaimer:
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.
Enquire About MEROKWIK-S
Fill the form below and we will get in touch with you